25 XP   0   0   10

Oasmia Pharmaceutical AB
Buy, Hold or Sell?

Let's analyse Oasmia Pharmaceutical AB together

PenkeI guess you are interested in Oasmia Pharmaceutical AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Oasmia Pharmaceutical AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Oasmia Pharmaceutical AB

I send you an email if I find something interesting about Oasmia Pharmaceutical AB.

Quick analysis of Oasmia Pharmaceutical AB (30 sec.)










What can you expect buying and holding a share of Oasmia Pharmaceutical AB? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.01
Expected worth in 1 year
$0.00
How sure are you?
27.3%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-29.7%

For what price can you sell your share?

Current Price per Share
$0.02
Expected price per share
$0.02 - $0.02
How sure are you?
50%

1. Valuation of Oasmia Pharmaceutical AB (5 min.)




Live pricePrice per Share (EOD)

$0.02

Intrinsic Value Per Share

$0.10 - $0.12

Total Value Per Share

$0.11 - $0.13

2. Growth of Oasmia Pharmaceutical AB (5 min.)




Is Oasmia Pharmaceutical AB growing?

Current yearPrevious yearGrowGrow %
How rich?$1.8m$18.3m-$16m-709.1%

How much money is Oasmia Pharmaceutical AB making?

Current yearPrevious yearGrowGrow %
Making money-$278.5k-$918.1k$639.5k229.6%
Net Profit Margin0.0%-1,765.6%--

How much money comes from the company's main activities?

3. Financial Health of Oasmia Pharmaceutical AB (5 min.)




What can you expect buying and holding a share of Oasmia Pharmaceutical AB? (5 min.)

Welcome investor! Oasmia Pharmaceutical AB's management wants to use your money to grow the business. In return you get a share of Oasmia Pharmaceutical AB.

What can you expect buying and holding a share of Oasmia Pharmaceutical AB?

First you should know what it really means to hold a share of Oasmia Pharmaceutical AB. And how you can make/lose money.

Speculation

The Price per Share of Oasmia Pharmaceutical AB is $0.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oasmia Pharmaceutical AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oasmia Pharmaceutical AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.01. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oasmia Pharmaceutical AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-15.5%-0.01-40.9%-0.02-95.9%-0.01-28.1%-0.01-26.2%
Usd Book Value Change Per Share0.00-11.3%0.00-7.4%-0.02-120.8%0.000.3%0.002.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-11.3%0.00-7.4%-0.02-120.8%0.000.3%0.002.3%
Usd Price Per Share0.00-0.03-0.29-1.00-1.16-
Price to Earnings Ratio-0.02--0.50--8.39--44,662,216.03--40,602,057.11-
Price-to-Total Gains Ratio-0.09--22.60-3.50--336.63--320.64-
Price to Book Ratio0.02-1.96-6.94-42.50-62.40-
Price-to-Total Gains Ratio-0.09--22.60-3.50--336.63--320.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.02
Number of shares50000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (50000 shares)-74.332.79
Gains per Year (50000 shares)-297.3311.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-297-3070111
20-595-60402212
30-892-90103323
40-1189-119804534
50-1487-149505645
60-1784-179206756
70-2081-208907867
80-2379-238608978
90-2676-2683010089
100-2973-29800111100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%2.020.00.09.1%2.020.00.09.1%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%5.015.00.025.0%6.016.00.027.3%6.016.00.027.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%5.015.00.025.0%6.016.00.027.3%6.016.00.027.3%

Fundamentals of Oasmia Pharmaceutical AB

About Oasmia Pharmaceutical AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Fundamental data was last updated by Penke on 2024-04-24 06:27:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Oasmia Pharmaceutical AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Oasmia Pharmaceutical AB earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oasmia Pharmaceutical AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,765.6%+1,765.6%
TTM-5Y-14,078.1%+14,078.1%
5Y-14,078.1%10Y-12,922.1%-1,156.0%
1.1.2. Return on Assets

Shows how efficient Oasmia Pharmaceutical AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • -27.6% Return on Assets means that Oasmia Pharmaceutical AB generated $-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oasmia Pharmaceutical AB:

  • The MRQ is -27.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.6%TTM-12.2%-15.4%
TTM-12.2%YOY-7.8%-4.4%
TTM-12.2%5Y-6.6%-5.6%
5Y-6.6%10Y-6.7%+0.1%
1.1.3. Return on Equity

Shows how efficient Oasmia Pharmaceutical AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • -30.7% Return on Equity means Oasmia Pharmaceutical AB generated $-0.31 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oasmia Pharmaceutical AB:

  • The MRQ is -30.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.7%TTM-13.5%-17.3%
TTM-13.5%YOY-8.3%-5.1%
TTM-13.5%5Y-8.0%-5.4%
5Y-8.0%10Y-8.4%+0.4%

1.2. Operating Efficiency of Oasmia Pharmaceutical AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Oasmia Pharmaceutical AB is operating .

  • Measures how much profit Oasmia Pharmaceutical AB makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oasmia Pharmaceutical AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-660.3%+660.3%
TTM-5Y-12,315.7%+12,315.7%
5Y-12,315.7%10Y-11,268.8%-1,046.9%
1.2.2. Operating Ratio

Measures how efficient Oasmia Pharmaceutical AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Oasmia Pharmaceutical AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY6.853-6.853
TTM-5Y136.325-136.325
5Y136.32510Y124.261+12.064

1.3. Liquidity of Oasmia Pharmaceutical AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Oasmia Pharmaceutical AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.51 means the company has $3.51 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Oasmia Pharmaceutical AB:

  • The MRQ is 3.509. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.621. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.509TTM4.621-1.112
TTM4.621YOY6.633-2.011
TTM4.6215Y3.372+1.249
5Y3.37210Y3.105+0.267
1.3.2. Quick Ratio

Measures if Oasmia Pharmaceutical AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 6.69 means the company can pay off $6.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oasmia Pharmaceutical AB:

  • The MRQ is 6.690. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.696. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.690TTM8.696-2.006
TTM8.696YOY10.728-2.032
TTM8.6965Y4.631+4.065
5Y4.63110Y4.237+0.394

1.4. Solvency of Oasmia Pharmaceutical AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Oasmia Pharmaceutical AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Oasmia Pharmaceutical AB to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.10 means that Oasmia Pharmaceutical AB assets are financed with 10.4% credit (debt) and the remaining percentage (100% - 10.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Oasmia Pharmaceutical AB:

  • The MRQ is 0.104. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.089. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.104TTM0.089+0.014
TTM0.089YOY0.062+0.027
TTM0.0895Y0.172-0.083
5Y0.17210Y0.190-0.018
1.4.2. Debt to Equity Ratio

Measures if Oasmia Pharmaceutical AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 11.6% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oasmia Pharmaceutical AB:

  • The MRQ is 0.116. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.098. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.098+0.017
TTM0.098YOY0.067+0.032
TTM0.0985Y0.227-0.129
5Y0.22710Y0.260-0.032

2. Market Valuation of Oasmia Pharmaceutical AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Oasmia Pharmaceutical AB generates.

  • Above 15 is considered overpriced but always compare Oasmia Pharmaceutical AB to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.02 means the investor is paying $-0.02 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oasmia Pharmaceutical AB:

  • The EOD is -1.617. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.016. Based on the earnings, the company is expensive. -2
  • The TTM is -0.497. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.617MRQ-0.016-1.601
MRQ-0.016TTM-0.497+0.481
TTM-0.497YOY-8.387+7.890
TTM-0.4975Y-44,662,216.030+44,662,215.533
5Y-44,662,216.03010Y-40,602,057.106-4,060,158.924
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oasmia Pharmaceutical AB:

  • The EOD is -10.480. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.105. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.096. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.480MRQ-0.105-10.375
MRQ-0.105TTM-7.096+6.991
TTM-7.096YOY-56.435+49.339
TTM-7.0965Y-173.807+166.711
5Y-173.80710Y-249.737+75.930
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Oasmia Pharmaceutical AB is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Oasmia Pharmaceutical AB:

  • The EOD is 1.989. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.020. Based on the equity, the company is cheap. +2
  • The TTM is 1.956. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.989MRQ0.020+1.969
MRQ0.020TTM1.956-1.936
TTM1.956YOY6.940-4.984
TTM1.9565Y42.497-40.541
5Y42.49710Y62.396-19.899
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Oasmia Pharmaceutical AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.001-34%-0.024+969%0.000-4156%0.000-595%
Book Value Per Share--0.0100.013-20%0.048-79%0.072-86%0.066-85%
Current Ratio--3.5094.621-24%6.633-47%3.372+4%3.105+13%
Debt To Asset Ratio--0.1040.089+16%0.062+67%0.172-40%0.190-45%
Debt To Equity Ratio--0.1160.098+18%0.067+74%0.227-49%0.260-56%
Dividend Per Share----0%-0%-0%-0%
Eps---0.003-0.008+165%-0.019+521%-0.006+82%-0.005+70%
Free Cash Flow Per Share--0.000-0.001+74%-0.002+263%-0.003+507%-0.003+468%
Free Cash Flow To Equity Per Share--0.000-0.001+143%0.000-57%-0.003+687%-0.002+623%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.124--------
Intrinsic Value_10Y_min--0.097--------
Intrinsic Value_1Y_max---0.012--------
Intrinsic Value_1Y_min---0.011--------
Intrinsic Value_3Y_max---0.017--------
Intrinsic Value_3Y_min---0.016--------
Intrinsic Value_5Y_max--0.000--------
Intrinsic Value_5Y_min---0.001--------
Market Cap3586960.000+99%35869.6004950004.800-99%93412797.750-100%1652665691.256-100%1595516314.096-100%
Net Profit Margin----0%-17.6560%-140.7810%-129.2210%
Operating Margin----0%-6.6030%-123.1570%-112.6880%
Operating Ratio----0%6.853-100%136.325-100%124.261-100%
Pb Ratio1.989+99%0.0201.956-99%6.940-100%42.497-100%62.396-100%
Pe Ratio-1.617-9900%-0.016-0.497+2973%-8.387+51754%-44662216.030+276136801295%-40602057.106+251033718689%
Price Per Share0.020+99%0.0000.028-99%0.293-100%0.999-100%1.157-100%
Price To Free Cash Flow Ratio-10.480-9900%-0.105-7.096+6671%-56.435+53751%-173.807+165751%-249.737+238205%
Price To Total Gains Ratio-8.846-9900%-0.088-22.603+25452%3.498-103%-336.632+380449%-320.644+362376%
Quick Ratio--6.6908.696-23%10.728-38%4.631+44%4.237+58%
Return On Assets---0.276-0.122-56%-0.078-72%-0.066-76%-0.067-76%
Return On Equity---0.307-0.135-56%-0.083-73%-0.080-74%-0.084-73%
Total Gains Per Share---0.002-0.001-34%-0.024+969%0.000-4156%0.000-595%
Usd Book Value--1803730.7662267719.920-20%18348423.528-90%36179161.769-95%33225732.769-95%
Usd Book Value Change Per Share---0.002-0.001-34%-0.024+969%0.000-4156%0.000-595%
Usd Book Value Per Share--0.0100.013-20%0.048-79%0.072-86%0.066-85%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.003-0.008+165%-0.019+521%-0.006+82%-0.005+70%
Usd Free Cash Flow---85568.990-148912.894+74%-633014.786+640%-1767006.584+1965%-1627616.171+1802%
Usd Free Cash Flow Per Share--0.000-0.001+74%-0.002+263%-0.003+507%-0.003+468%
Usd Free Cash Flow To Equity Per Share--0.000-0.001+143%0.000-57%-0.003+687%-0.002+623%
Usd Market Cap3586960.000+99%35869.6004950004.800-99%93412797.750-100%1652665691.256-100%1595516314.096-100%
Usd Price Per Share0.020+99%0.0000.028-99%0.293-100%0.999-100%1.157-100%
Usd Profit---554434.906-278510.095-50%-918102.367+66%-1890365.727+241%-1761075.404+218%
Usd Revenue----0%2210.195-100%1057710.184-100%964609.061-100%
Usd Total Gains Per Share---0.002-0.001-34%-0.024+969%0.000-4156%0.000-595%
 EOD+5 -3MRQTTM+10 -19YOY+13 -185Y+16 -1510Y+16 -15

3.2. Fundamental Score

Let's check the fundamental score of Oasmia Pharmaceutical AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.617
Price to Book Ratio (EOD)Between0-11.989
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.690
Current Ratio (MRQ)Greater than13.509
Debt to Asset Ratio (MRQ)Less than10.104
Debt to Equity Ratio (MRQ)Less than10.116
Return on Equity (MRQ)Greater than0.15-0.307
Return on Assets (MRQ)Greater than0.05-0.276
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Oasmia Pharmaceutical AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.020
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-10-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets21,897
Total Liabilities2,270
Total Stockholder Equity19,627
 As reported
Total Liabilities 2,270
Total Stockholder Equity+ 19,627
Total Assets = 21,897

Assets

Total Assets21,897
Total Current Assets7,965
Long-term Assets13,931
Total Current Assets
Cash And Cash Equivalents 426
Short-term Investments 7,219
Net Receivables 321
Total Current Assets  (as reported)7,965
Total Current Assets  (calculated)7,965
+/-0
Long-term Assets
Long-term Assets Other 13,902
Long-term Assets  (as reported)13,931
Long-term Assets  (calculated)13,902
+/- 30

Liabilities & Shareholders' Equity

Total Current Liabilities2,270
Long-term Liabilities0
Total Stockholder Equity19,627
Total Current Liabilities
Accounts payable 274
Other Current Liabilities 1,996
Total Current Liabilities  (as reported)2,270
Total Current Liabilities  (calculated)2,270
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock5,339
Retained Earnings -187,605
Accumulated Other Comprehensive Income 458
Other Stockholders Equity 201,435
Total Stockholder Equity (as reported)19,627
Total Stockholder Equity (calculated)19,627
+/-0
Other
Cash and Short Term Investments 7,645
Common Stock Shares Outstanding 179,348
Liabilities and Stockholders Equity 21,897
Net Debt -426
Net Working Capital 5,696



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-31
> Total Assets 
61,277
65,332
562,829
614,719
669,300
600,083
876,470
1,005,347
942,781
915,239
823,760
761,289
693,303
594,308
701,760
63,577
51,655
34,155
31,856
28,416
26,093
21,897
21,89726,09328,41631,85634,15551,65563,577701,760594,308693,303761,289823,760915,239942,7811,005,347876,470600,083669,300614,719562,82965,33261,277
   > Total Current Assets 
5,635
11,557
67,891
144,710
176,046
107,489
384,735
532,215
473,820
416,079
350,382
289,074
228,322
136,495
250,842
20,284
16,236
14,427
12,315
9,956
8,079
7,965
7,9658,0799,95612,31514,42716,23620,284250,842136,495228,322289,074350,382416,079473,820532,215384,735107,489176,046144,71067,89111,5575,635
       Cash And Cash Equivalents 
66
503
7,599
116,272
108,797
29,039
24,757
201,018
47,840
52,558
12,108
3,893
7,185
7,912
4,675
167
216
909
476
288
383
426
4263832884769092161674,6757,9127,1853,89312,10852,55847,840201,01824,75729,039108,797116,2727,59950366
       Short-term Investments 
0
0
0
0
0
0
280,245
234,080
306,180
277,030
207,375
172,409
142,492
89,357
69,282
18,260
14,584
12,769
11,024
9,177
7,331
7,219
7,2197,3319,17711,02412,76914,58418,26069,28289,357142,492172,409207,375277,030306,180234,080280,245000000
       Net Receivables 
2,174
9,135
4,259
3,534
3,493
3,583
44,625
66,245
42,926
44,552
44,815
47,171
49,789
23,908
162,294
392
278
361
307
308
156
321
321156308307361278392162,29423,90849,78947,17144,81544,55242,92666,24544,6253,5833,4933,5344,2599,1352,174
       Inventory 
1,278
1,215
12,607
7,420
9,550
16,484
18,385
28,837
31,281
51,496
51,322
28,319
16,196
9,897
9,897
870
723
0
0
0
0
0
000007238709,8979,89716,19628,31951,32251,49631,28128,83718,38516,4849,5507,42012,6071,2151,278
   > Long-term Assets 
0
0
0
470,009
493,254
492,595
491,735
473,132
468,961
459,853
473,379
472,215
464,981
457,813
450,918
43,293
35,419
19,728
19,541
18,461
18,014
13,931
13,93118,01418,46119,54119,72835,41943,293450,918457,813464,981472,215473,379459,853468,961473,132491,735492,595493,254470,009000
       Property Plant Equipment 
1,673
1,584
0
14,701
37,875
37,415
35,941
28,014
28,937
17,630
15,604
20,136
18,593
17,108
15,895
1,395
1,171
1,244
1,197
1,070
943
0
09431,0701,1971,2441,1711,39515,89517,10818,59320,13615,60417,63028,93728,01435,94137,41537,87514,70101,5841,673
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
173,838
171,603
170,177
168,118
0
0168,118170,177171,603173,83800000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000
       Intangible Assets 
5,230
5,024
479,986
453,308
453,376
453,178
453,792
443,116
438,021
432,926
457,472
451,777
446,087
440,404
434,722
41,868
34,220
18,455
18,315
17,363
17,043
0
017,04317,36318,31518,45534,22041,868434,722440,404446,087451,777457,472432,926438,021443,116453,792453,178453,376453,308479,9865,0245,230
       Long-term Assets Other 
0
0
494,938
-2
1
492,595
491,735
0
1
1
1
0
0
0
0
0
0
0
0
0
0
13,902
13,90200000000001110491,735492,5951-2494,93800
> Total Liabilities 
24,677
21,596
163,482
221,541
241,183
192,987
153,785
185,958
173,977
201,642
184,163
178,617
141,234
44,595
43,750
3,348
2,500
2,923
2,444
2,790
2,054
2,270
2,2702,0542,7902,4442,9232,5003,34843,75044,595141,234178,617184,163201,642173,977185,958153,785192,987241,183221,541163,48221,59624,677
   > Total Current Liabilities 
24,677
18,015
130,660
188,719
195,779
181,720
143,612
177,112
166,480
176,800
180,818
171,685
135,246
39,454
39,423
2,981
2,190
2,425
1,986
2,412
1,739
2,270
2,2701,7392,4121,9862,4252,1902,98139,42339,454135,246171,685180,818176,800166,480177,112143,612181,720195,779188,719130,66018,01524,677
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
298
252
287
303
268
242
0
0242268303287252298000000000000000
       Short Long Term Debt 
0
0
85,786
139,568
140,798
80,000
80,000
89,670
80,000
80,000
80,000
80,000
80,000
0
0
0
0
0
0
0
0
0
00000000080,00080,00080,00080,00080,00089,67080,00080,000140,798139,56885,78600
       Accounts payable 
1,768
1,617
17,032
17,666
13,910
14,516
14,228
22,524
13,929
10,678
12,401
8,016
6,186
13,590
4,540
787
590
672
188
441
320
274
2743204411886725907874,54013,5906,1868,01612,40110,67813,92922,52414,22814,51613,91017,66617,0321,6171,768
       Other Current Liabilities 
369
368
3,309
141
8,248
53,273
8,853
30,286
3,910
4,659
4,096
2,823
4,942
3,307
16,343
1,896
1,347
1,467
1,495
1,703
1,177
1,996
1,9961,1771,7031,4951,4671,3471,89616,3433,3074,9422,8234,0964,6593,91030,2868,85353,2738,2481413,309368369
   > Long-term Liabilities 
0
0
32,822
32,822
45,404
11,267
10,173
8,846
7,497
6,298
3,345
6,932
5,988
5,141
4,327
367
310
497
459
378
315
0
03153784594973103674,3275,1415,9886,9323,3456,2987,4978,84610,17311,26745,40432,82232,82200
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
12,582
11,268
10,173
14,165
12,842
12,093
6,178
10,578
12,117
10,428
7,739
6,518
5,992
7,881
7,590
6,710
5,807
0
05,8076,7107,5907,8815,9926,5187,73910,42812,11710,5786,17812,09312,84214,16510,17311,26812,5820000
       Other Liabilities 
0
3,580
0
32,822
32,822
-1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000010-132,82232,82203,5800
> Total Stockholder Equity
36,601
43,738
399,347
393,178
428,117
407,096
722,685
819,389
768,804
713,597
639,597
582,672
552,069
549,713
658,010
60,229
49,155
31,232
29,411
25,626
24,039
19,627
19,62724,03925,62629,41131,23249,15560,229658,010549,713552,069582,672639,597713,597768,804819,389722,685407,096428,117393,178399,34743,73836,601
   Common Stock
2,039
2,121
0
22,490
24,909
24,909
44,837
44,837
44,837
44,837
44,837
44,837
44,837
44,837
49,674
5,251
4,848
5,164
5,189
4,981
4,952
5,339
5,3394,9524,9815,1895,1644,8485,25149,67444,83744,83744,83744,83744,83744,83744,83744,83724,90924,90922,49002,1212,039
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40
36
37
38
36
191,784
458
458191,7843638373640000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
-3
288
0
-651
-734
-821
-894
-1,211
1,097
-743
-349
0
0
427
4,547
198,033
182,864
194,763
195,699
187,877
-4,952
201,435
201,435-4,952187,877195,699194,763182,864198,0334,54742700-349-7431,097-1,211-894-821-734-6510288-3



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-04-30)

Gross Profit (+$)
totalRevenue100
Cost of Revenue-35,576
Gross Profit-35,476-35,476
 
Operating Income (+$)
Gross Profit-35,476
Operating Expense-0
Operating Income-35,476-35,476
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense00
 
Net Interest Income (+$)
Interest Income20
Interest Expense-49
Other Finance Cost-446
Net Interest Income-475
 
Pretax Income (+$)
Operating Income-35,476
Net Interest Income-475
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,249-35,703
EBIT - interestExpense = -35,525
-35,251
-35,201
Interest Expense49
Earnings Before Interest and Taxes (EBIT)-35,476-35,201
Earnings Before Interest and Taxes (EBITDA)-10,164
 
After tax Income (+$)
Income Before Tax-35,249
Tax Provision-0
Net Income From Continuing Ops-356,719-35,249
Net Income-35,249
Net Income Applicable To Common Shares-166,678
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses35,576
Total Other Income/Expenses Net227475
 

Technical Analysis of Oasmia Pharmaceutical AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oasmia Pharmaceutical AB. The general trend of Oasmia Pharmaceutical AB is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oasmia Pharmaceutical AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oasmia Pharmaceutical AB.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.02 < 0.02 < 0.02.

The bearish price targets are: 0.02 > 0.02 > 0.02.

Tweet this
Oasmia Pharmaceutical AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oasmia Pharmaceutical AB. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oasmia Pharmaceutical AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Moving Average Convergence/Divergence (MACD) ChartOasmia Pharmaceutical AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oasmia Pharmaceutical AB. The current adx is .

Oasmia Pharmaceutical AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Relative Strength Index (RSI) ChartOasmia Pharmaceutical AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Stochastic Oscillator ChartOasmia Pharmaceutical AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Commodity Channel Index (CCI) ChartOasmia Pharmaceutical AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Chande Momentum Oscillator (CMO) ChartOasmia Pharmaceutical AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Williams %R ChartOasmia Pharmaceutical AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Average True Range (ATR) ChartOasmia Pharmaceutical AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily On-Balance Volume (OBV) ChartOasmia Pharmaceutical AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oasmia Pharmaceutical AB.

Oasmia Pharmaceutical AB Daily Money Flow Index (MFI) ChartOasmia Pharmaceutical AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oasmia Pharmaceutical AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Oasmia Pharmaceutical AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oasmia Pharmaceutical AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.020
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Oasmia Pharmaceutical AB with someone you think should read this too:
  • Are you bullish or bearish on Oasmia Pharmaceutical AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oasmia Pharmaceutical AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oasmia Pharmaceutical AB

I send you an email if I find something interesting about Oasmia Pharmaceutical AB.


Comments

How you think about this?

Leave a comment

Stay informed about Oasmia Pharmaceutical AB.

Receive notifications about Oasmia Pharmaceutical AB in your mailbox!